13D·WATCH Activist + Insider Intelligence Live feed Blog About Pricing
SCHEDULE 13D Filed 2026-06-11 Event 2026-06-04 SEC 0001104659-26-073089 →

D. E. SHAW & CO, L.P. Gossamer Bio, Inc. GOSS

Stake: 9.50% Shares: 43,915,249 CUSIP: 38341P102 Class: Common Stock, $0.0001 par value per share

Item 4 — Purpose of Transaction

The information set forth in Item 3 of this Schedule 13D is incorporated herein by reference. Summary of May 18, 2026 Agreements On May 18, 2026, the Issuer commenced an exchange offer (the "Exchange Offer") to exchange any and all of its 5.00% Convertible Senior Notes due 2027 (the "Existing Convertible Notes") for a pro rata portion of (i) up to $72.0 million in aggregate principal amount of its new 7.50% Convertible Senior Secured First Lien Notes due 2030 (the "New Convertible Notes"), (ii) up to 317,647,058 Common Shares (the Common Shares issued in the Exchange Offer, the "New Shares") or, in lieu of issuing Common Shares to the extent any investor would beneficially own greater than 9.99% of the outstanding Common Shares, prefunded warrants to purchase Common Shares (the "Prefunded Warrants") and (iii) up to 150,000,000 warrants to purchase Common Shares (the "Purchase Warrants"). On June 4, 2026, following receipt of the requisite consents in the concurrent solicitation of consents (the "Consent Solicitation") from holders of the Existing Convertible Notes, the Issuer and Wilmington Trust, National Association, as trustee under the indenture, dated as of May 21, 2020, and a first supplemental indenture, dated as of May 21, 2020 (together, the "Existing Convertible Notes Indenture"), entered into a supplemental indenture to eliminate substantially all of the restrictive covenants, certain of the default provisions and certain other provisions contained in the Existing Convertible Notes Indenture. Also on May 18, 2026, holders of approximately 75.2% of the Existing Convertible Notes, including Valence and Cogence (the "Supporting Noteholders"), entered into a transaction support agreement with the Issuer (the "Transaction Support Agreement") to support the Exchange Offer and Consent Solicitation, including by tendering all of their Existing Convertible Notes in the Exchange Offer and delivering related consents. $30,290,000 aggregate principal amount of Existing Convertible Notes held by Valence and Cogence collectively were tendered to the Issuer prior to 5:00 p.m., New York City time, on June 2, 2026 (the "Extended Early Tender Date"). The exchange of New Convertible Notes, New Shares, and Purchase Warrants for Valence's and Cogence's Existing Convertible Notes was finalized on June 4, 2026 (the "Early Settlement Date"). On the Early Settlement Date, and in exchange for their Existing Convertible Notes, Valence received $10,369,000 aggregate principal amount of New Convertible Notes, 45,745,939 New Shares, and 21,602,250 Purchase Warrants, plus accrued and unpaid interest on such Existing Convertible Notes from, and including, the most recent interest payment date to, but excluding, the Early Settlement Date, equal to $12,006.25, and Cogence received $535,000.00 aggregate principal amount of New Convertible Notes, 2,361,705 New Shares, and 1,115,250 Purchase Warrants, plus accrued and unpaid interest on such Existing Convertible Notes from, and including, the most recent interest payment date to, but excluding, the Early Settlement Date, equal to $619.58. In connection with the early settlement of the Exchange Offer, the Issuer issued $65,174,000 in aggregate principal amount of New Convertible Notes, 254,150,441 New Shares, 33,402,727 Prefunded Warrants and 135,789,000 Purchase Warrants in exchange for the validly tendered and accepted Existing Convertible Notes. Contemporaneously with their entrance into the Transaction Support Agreement, each of Valence and Cogence entered into a voting agreement (the "Voting Agreements") with the Issuer whereby Valence and Cogence agreed to appear at the Issuer's special meeting of stockholders to be held following the Exchange Offer (including any adjournment or postponement thereof, the "Special Meeting") or otherwise cause the New Shares received by them in the Exchange Offer to be counted as present thereat for purposes of determining a quorum, and be present (in person or by proxy) and vote, or cause to be voted, all of the New Shares beneficially owned by them in favor of the Stockholder Proposals (as defined below). It was a condition to the Exchange Offer and Consent Solicitation that valid, binding and enforceable agreements provided by Supporting Noteholders to vote the New Shares received in the Exchange Offer in favor of the Stockholder Proposals were in place with respect to the New Shares to be held by the parties to the Transaction Support Agreement. On June 9, 2026, the Issuer filed a definitive proxy statement with the SEC announcing that the Special Meeting will be held on July 14, 2026, at 9:00 a.m. Pacific Time, unless postponed or adjourned to a later date. Exchange Offer Memorandum and Consent Solicitation Statement The Exchange Offer and Consent Solicitation will expire at 5:00 p.m., New York City time, on June 16, 2026 (such time and date, as the same may be extended, the "Expiration Deadline"), unless extended or earlier terminated. The

Cross-References

Insider Activity (last 365d)
0 transactions
0 buys · 0 sales · 0 awards/exercises
Issuer Cluster
6 13D/G filings on this issuer
5 other filings besides this one
Filer Track Record
14 filings by this filer
13 other filings in the data moat
Short Interest · settle 2026-07-15
DTC 3.79
73,178,841 shares short · +36.3% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers
1 holder · $388K
Point72 Asset Mgmt

Post-Filing Returns · since 2026-06-04 on GOSS

+1 day
0.0%
+5 days
0.0%
+30 days
0.0%
+60 days
+90 days
+180 days

Anchor price 0.18 on closest trading day on/after 2026-06-04. Source: Yahoo Finance daily adj_close (split + dividend adjusted).

Other 13D/G Filings on Gossamer Bio, Inc.

FiledFormFilerStakeShares
2026-07-24 SCHEDULE 13D/A D. E. SHAW & CO, L.P. 7.10% 32,642,631 view →
2026-07-01 SCHEDULE 13D/A D. E. SHAW & CO, L.P. 8.30% 38,362,468 view →
2026-06-11 SCHEDULE 13G DeepCurrents Investment Group LLC view →
2026-06-11 SCHEDULE 13G 683 Capital Management, LLC view →
2026-06-09 SCHEDULE 13G Context Capital Management, LLC view →

Other Filings by D. E. SHAW & CO, L.P.

FiledFormIssuerStakeShares
2026-07-24 SCHEDULE 13D/A Gossamer Bio, Inc. 7.10% 32,642,631 view →
2026-07-17 SCHEDULE 13G CleanSpark, Inc. view →
2026-07-09 SCHEDULE 13G Alight, Inc. ALIT view →
2026-07-02 SCHEDULE 13G Inspire Medical Systems, Inc. INSP view →
2026-07-02 SCHEDULE 13G Agios Pharmaceuticals, Inc. AGIO view →
2026-07-01 SCHEDULE 13D/A Gossamer Bio, Inc. GOSS 8.30% 38,362,468 view →
2026-06-22 SCHEDULE 13G Cracker Barrel Old Country Store, Inc. CBRL view →
2026-06-03 SCHEDULE 13D/A Enviri Corporation 0 view →
2026-06-03 SCHEDULE 13G Enviri Corporation NVRI view →
2024-10-09 SC DIVERSIFIED HEALTHCARE TRUST DHCNL view →
2023-10-05 SC DIVERSIFIED HEALTHCARE TRUST DHCNL view →
2023-07-18 SC DIVERSIFIED HEALTHCARE TRUST DHCNL view →
2021-11-10 SC Decarbonization Plus Acquisition Corp III SLDPW view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →